Antibiotic resistance is a growing global crisis, increasing the urgency for effective treatments. While Medivir now focuses on cancer therapies, it has a legacy in antimicrobial research. This was highlighted by Infex Therapeutics licensing agreement with Venus Remedies Ltd for the development of MET-X in India - a compound developed from a research program that Medivir outlicensed in 2017. We reached out to Medivir's CEO Jens Lindberg for a comment.